Supports exercise performance and recovery by optimizing levels of nitric oxide (NO) and may decrease lactic acid accumulation in muscles.*
Weight loss is important, but clinicians may also consider A1C, blood pressure, lipids, cardiovascular risk, liver fat, tolerability, medication interactions, quality of life, and long-term maintenance
There is local legislation and supply chain concerns
Overexpression of HK2 not only accelerates glucose uptake, but also activates multiple pathways required for glucose influx into Kras-driven PC growth, including the pentose phosphate pathway, serine synthesis pathway, and hexosamine biosynthesis pathway, which protomes the proliferation, invasion, and metastasis of PC (46, 47)
In the Phase 2 clinical trial, participants generally met the following criteria: Body mass index (BMI) of 27 kg/m or above with at least one weight-related comorbidity (such as hypertension, dyslipidaemia, or obstructive sleep apnoea), or a BMI of 30 kg/m or above without comorbidities
Check the formulary list: The drug formulary is a list of medications covered by your insurance plan
